SCHEDULE 13G/A: DG Capital Management Reduces Stake in Fennec Pharmaceuticals Below 5%

Sentiment:

Beneficial Ownership Amendment 14 February 2025 5:06 PM

📋All filings for Fennec Pharmaceuticals INC

DG Capital Management, LLC and affiliated entities have reported a reduction in their beneficial ownership of Fennec Pharmaceuticals Inc. common shares to 4.1%, falling below the 5% threshold.

Worse than expectedThe filing indicates that DG Capital Management, LLC and Dov Gertzulin's beneficial ownership has decreased to 4.1%, falling below the 5% threshold that typically triggers Schedule 13G reporting. This reduction in stake by a notable institutional investor could be perceived as a negative signal by the market.

Summary

DG Capital Management, LLC, DG Value Partners II Master Fund, LP, and Dov Gertzulin filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership of Fennec Pharmaceuticals Inc. Common Shares.
As of December 31, 2024, DG Capital Management, LLC and Dov Gertzulin beneficially own 1,114,692 shares, representing 4.1% of the outstanding common shares.
DG Value Partners II Master Fund, LP beneficially owns 953,407 shares, representing 3.5% of the outstanding common shares.
All reporting persons hold shared voting and dispositive power over their respective reported shares.
The percentages are calculated based on 27,432,234 common shares outstanding, as reported in Fennec Pharmaceuticals Inc.'s most recent Form 10-Q filed on November 8, 2024.
The filing indicates that the reporting persons' aggregate beneficial ownership has fallen below the 5% threshold, triggering this amendment.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reduction in beneficial ownership by a significant institutional investor, which could be interpreted as a decrease in confidence or a strategic divestment, although the filing itself is a routine disclosure.

Negatives

The reporting persons, including DG Capital Management, LLC and Dov Gertzulin, have reduced their beneficial ownership in Fennec Pharmaceuticals Inc. to below 5% (specifically 4.1%), indicating a decrease in their investment stake.

Risks

The reduction in beneficial ownership by DG Capital Management, LLC and affiliated entities to below 5% may be interpreted by the market as a decrease in confidence or a portfolio rebalancing, potentially impacting investor sentiment and stock price.

Future Outlook

Industry Context

Stakeholder Impact

Shareholders: The reduction in a significant institutional stake may lead to negative investor sentiment or increased selling pressure on the stock.

Key Dates

Date	Description
2024-11-08	Date of Fennec Pharmaceuticals Inc.'s most recently filed Form 10-Q, which provided the basis for the total shares outstanding (27,432,234 shares).
2024-12-31	Date of event which requires filing of this statement (reporting period end date).
2025-02-14	Date of filing of this Schedule 13G Amendment No. 2.

Keywords

Fennec Pharmaceuticals Inc., DG Capital Management, DG Value Partners II Master Fund, Dov Gertzulin, Schedule 13G, Beneficial Ownership, Common Shares, SEC Filing, Institutional Ownership, Investment Management

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.